Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis reported its share and voting rights data for January 31, 2023. The company has a total of 45,675,968 shares in capital and 51,743,288 voting rights. Cellectis specializes in gene-editing technology, focusing on innovative CAR-T therapies for cancer treatment and using its TALEN® platform to develop various therapies. Based in Paris, with operations in New York and Raleigh, Cellectis aims to address unmet medical needs through its leading-edge approaches in cell and gene therapies.

Positive

• Cellectis has developed a pioneering gene-editing platform, TALEN®, enhancing its product candidates.
• Focused on cancer therapies, Cellectis targets high-need conditions like acute myeloid leukemia and multiple myeloma.
• Company operates in key regions including Paris, New York, and Raleigh, expanding its market reach.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
01/31/2023	45,675,968	51,743,288

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contact:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Attachment

• Voting_Rights_PR_January_EN_docx

FAQ

What is Cellectis' total number of shares as of January 31, 2023?

Cellectis has a total of 45,675,968 shares in capital as of January 31, 2023.

How many voting rights does Cellectis have as of January 31, 2023?

As of January 31, 2023, Cellectis has 51,743,288 voting rights.

What innovative technology does Cellectis use in its therapies?

Cellectis utilizes the TALEN® gene-editing technology for its product candidates.

What types of cancer does Cellectis aim to treat?

Cellectis focuses on treating cancers such as acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS.